Mylan Stock Buy Or — Sell
The company is focusing on higher-margin generic launches and its innovative portfolio, including late-stage assets expected to complete enrollment in 2026. Market Cap: ~$17.25 billion as of April 2026.
~$14.67, indicating a slight forecasted downside of roughly -1% . Target Range: High of $18.00 and a low of $10.00 . Investment Case: Buy vs. Sell Buy Case (Bullish) Sell/Hold Case (Bearish) mylan stock buy or sell
AI responses may include mistakes. For financial advice, consult a professional. Learn more The company is focusing on higher-margin generic launches
Discounted Cash Flow (DCF) models suggest the stock is significantly undervalued, with some estimates placing "fair value" as high as $56.03 . Target Range: High of $18
The consensus among Wall Street analysts is currently a . While some analysts maintain a "Buy" rating, recent price targets suggest limited immediate upside. Current Stock Price: ~$14.81 (as of April 27, 2026).
Viatris is currently viewed as a value play or income stock rather than a high-growth candidate. Its low valuation and steady dividends may make it a "buy" for long-term holders, while short-term traders might "hold" or "sell" due to flat price targets and operational headwinds.